Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Summary

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Early Stage Triple-Negative Breast Carcinoma
• Metastatic Bladder Urothelial Carcinoma
• Metastatic Cervical Carcinoma
• Metastatic Clear Cell Renal Cell Carcinoma
• Metastatic Colorectal Carcinoma
• Metastatic Endometrial Carcinoma
• Metastatic Esophageal Carcinoma
• Metastatic Liver Carcinoma
• Metastatic Lung Non-Small Cell Carcinoma
• Metastatic Malignant Skin Neoplasm
• Metastatic Malignant Solid Neoplasm
• Resectable Lung Non-Small Cell Carcinoma
• Early Stage Lung Non-Small Cell Carcinoma
• Resectable Malignant Solid Neoplasm
• Resectable Triple-Negative Breast Carcinoma
• Stage III Renal Cell Cancer AJCC v8
• Stage IV Cervical Cancer AJCC v8
• Stage IV Renal Cell Cancer AJCC v8
• Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
• Recurrent Cervical Carcinoma
• Recurrent Colorectal Carcinoma
• Recurrent Endometrial Carcinoma
• Recurrent Esophageal Carcinoma
• Recurrent Liver Carcinoma
• Recurrent Lung Non-Small Cell Carcinoma
• Recurrent Malignant Skin Neoplasm
• Recurrent Malignant Solid Neoplasm

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Mayo Clinic

Last updated on ClinicalTrials.gov

March 12, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites